Skip to main content
. 2019 Aug 15;11(8):1187. doi: 10.3390/cancers11081187

Figure 3.

Figure 3

Effects of 4-methylubelliferone (4-MU) and carboplatin on ovarian cancer cell survival and HA production. (a) Ovarian cancer cell survival following 72 h of 4-MU (1 mM) treatment. The black and grey bars represent chemosensitive and chemoresistant cells, respectively. Data are expressed as percentage of control, mean ± SEM from 2–3 independent experiments performed in triplicate. *, significantly different from control media treatment (p < 0.05, independent t test). (b). Effect of 4-MU (1 mM) 72 h on HA production in conditioned media measured by HA ELISA. Data are expressed as ng/mL from 4–6 determinations. *, significantly different from control treatment (p < 0.05, independent t test). Effect of 4-MU on survival of OV-90 (c), chemosensitive primary cells (n = 2) (d), SKOV3 (e), and chemoresistant primary cells (n = 8), (f) assessed by MTT assay. Cells were treated with phosphate buffered saline (PBS), control, 4-MU (1 mM), carboplatin (CBP, 100 µM), and 4-MU (1 mM) + CBP (100 µM) for 72 h. Data are expressed as % of control from 2–5 independent experiments performed in quadruplicate. Effects of 4-MU (1 mM) and/or CBP (100 µM) treatment on apoptosis measured by caspase 3/7 cleavage in primary serous ovarian cancer cells. (g) chemosensitive (n = 3), and (h) chemoresistant (n = 5) cells. (a–h) *, significantly different from control, **, significantly different from CBP treatment, ***, significantly different from 4-MU treatment, (p < 0.05, one way ANOVA, Tukey’s multiple comparisons test).